Literature DB >> 28163167

De-isolation of patients with pulmonary tuberculosis after start of treatment - clear, unequivocal guidelines are missing.

Eskild Petersen1, Faryal Khamis2, Giovanni Battista Migliori3, Julie Glerup Bay4, Ben Marais5, Christian Wejse6, Alimuddin Zumla7.   

Abstract

The study review guidelines on isolation of patients with tuberculosis, TB, from the World Health Organization, WHO, Centers for Disease Control and Prevention, CDC, and the European Center for Disease Control, ECDC. The review found that unequivocal guidelines for removing patients out of negative-pressure isolation and de-isolation patients from either single rooms or isolation at home is needed. Studies show that the time of effective treatment is the key parameter to follow to determine if patients are contagious to others or not. This means that standard treatment of multi-drug resistant, MDR, TB will not result in the patient being non-infectious. Thus it is important right from the time of diagnosis to know if the patient is infected with MDR TB or not. Thus the early use of molecular techniques to reveal drug susceptibility is important. Clear guidelines stating if patient with microscopy negative sputum no matter infected with fully susceptible or MDR TB, no matter HIV positive or not is needed.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  De-isolation; Isolation; Molecular diagnosis; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28163167     DOI: 10.1016/j.ijid.2017.01.029

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  1 in total

1.  Impact of prolonged isolation on adolescents with drug-susceptible tuberculosis in Lima, Peru: a qualitative study.

Authors:  Victoria Elena Oliva Rapoport; Elmer Altamirano; Liz Senador; Milagros Wong; Catherine B Beckhorn; Julia Coit; Stephanie D Roche; Leonid Lecca; Jerome T Galea; Silvia S Chiang
Journal:  BMJ Open       Date:  2022-09-20       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.